Patients demographics and main pathologic features
| Characteristics . | No. of patients; n = 109 . | |
|---|---|---|
| Age (y) | ||
| <40 | 22 (20%) | |
| ≥40 | 87 (80%) | |
| Sex | ||
| Male | 47 (43%) | |
| Female | 62 (57%) | |
| Von Hippel-Lindau disease | ||
| Present | 12 (11%) | |
| Absent | 97 (89%) | |
| Multiple endocrine neoplasia type 1 disease | ||
| Present | 5 (5%) | |
| Absent | 104 (95%) | |
| Functional syndrome | ||
| Present | 24 (22%) | |
| Absent | 85 (78%) | |
| Size | ||
| ≤20 mm | 37 (34%) | |
| >20 mm | 72 (66%) | |
| Classification according to WHO 2000 | ||
| Benign endocrine tumors | 31 (28%) | |
| Endocrine tumors of uncertain behavior | 27 (25%) | |
| Well-differentiated endocrine carcinomas | 51 (47%) | |
| Staging according to TNM 2006* | ||
| Stage 1 | 31(28%) | |
| Stage 2 | 24 (22%) | |
| Stage 3 | 28 (26%) | |
| Stage 4 | 26 (24%) | |
| Grading according to TNM 2006* | ||
| Grade G1 | 41 (38%) | |
| Grade G2 | 63 (58%) | |
| Grade G3 | 5 (4%) | |
| Necrosis | ||
| No necrosis | 97 (89%) | |
| Presence of necrosis | 12 (11%) | |
| Ki-67 (%) | ||
| ≤2 | 55 (50%) | |
| >2 | 54 (50%) | |
| Lymph node metastasis | ||
| Absent | 67 (61%) | |
| Present | 42 (39%) | |
| Liver metastasis | ||
| Absent | 83 (76%) | |
| Present | 26 (24%) | |
| Duration of follow-up (mo) | ||
| Median | 22 | |
| Range | 1-130 | |
| Lost to follow-up | 7 | |
| Death | 8 | |
| Characteristics . | No. of patients; n = 109 . | |
|---|---|---|
| Age (y) | ||
| <40 | 22 (20%) | |
| ≥40 | 87 (80%) | |
| Sex | ||
| Male | 47 (43%) | |
| Female | 62 (57%) | |
| Von Hippel-Lindau disease | ||
| Present | 12 (11%) | |
| Absent | 97 (89%) | |
| Multiple endocrine neoplasia type 1 disease | ||
| Present | 5 (5%) | |
| Absent | 104 (95%) | |
| Functional syndrome | ||
| Present | 24 (22%) | |
| Absent | 85 (78%) | |
| Size | ||
| ≤20 mm | 37 (34%) | |
| >20 mm | 72 (66%) | |
| Classification according to WHO 2000 | ||
| Benign endocrine tumors | 31 (28%) | |
| Endocrine tumors of uncertain behavior | 27 (25%) | |
| Well-differentiated endocrine carcinomas | 51 (47%) | |
| Staging according to TNM 2006* | ||
| Stage 1 | 31(28%) | |
| Stage 2 | 24 (22%) | |
| Stage 3 | 28 (26%) | |
| Stage 4 | 26 (24%) | |
| Grading according to TNM 2006* | ||
| Grade G1 | 41 (38%) | |
| Grade G2 | 63 (58%) | |
| Grade G3 | 5 (4%) | |
| Necrosis | ||
| No necrosis | 97 (89%) | |
| Presence of necrosis | 12 (11%) | |
| Ki-67 (%) | ||
| ≤2 | 55 (50%) | |
| >2 | 54 (50%) | |
| Lymph node metastasis | ||
| Absent | 67 (61%) | |
| Present | 42 (39%) | |
| Liver metastasis | ||
| Absent | 83 (76%) | |
| Present | 26 (24%) | |
| Duration of follow-up (mo) | ||
| Median | 22 | |
| Range | 1-130 | |
| Lost to follow-up | 7 | |
| Death | 8 | |
Proposed classification, ref. 17.